The Shareholders Foundation announces that an investigation on behalf of investors of NewLink Genetics Corp (NASDAQ:NLNK) shareswas launched over potential securities laws violations by NewLink Genetics and certain of its directors and officers.
Investors who purchased shares of NewLink Genetics Corp (NASDAQ:NLNK) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of NewLink Genetics Corp (NASDAQ:NLNK) concerning whether a series of statements by NewLink Genetics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
NewLink Genetics Corp reported that its annual Total Revenue declined from $2.08 million in 2010 to $1.09 million in 2013 and that its respective Net Loss increased from $16.21 million to $31.18 million. Shares of NewLink Genetics Corp (NASDAQ:NLNK) grew from $6.44 per share in December 2011 to as high as $46.50 per share in February 2014.
On October 1, 2014, NewLink Genetics Corp announced that Jack Henneman has been appointed Executive Vice President and Chief Financial Officer, effective immediately and that Mr. Henneman replaces Gordon H. Link, Jr., Chief Financial Officer. Shares of NewLink Genetics Corp (NASDAQ:NLNK) declined to as low as $17.32 per share on October 13, 2014.
Those who purchased shares of NewLink Genetics Corp (NASDAQ:NLNK) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com